StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $59.66 | $59.27 | -0.65% | 0.1M |
| 05-18 | $60.01 | $56.25 | -6.27% | 0.3M |
| 05-19 | $55.50 | $55.20 | -0.54% | 0.3M |
| 05-20 | $55.78 | $64.95 | +16.44% | 0.3M |
| 05-21 | $64.30 | $61.27 | -4.71% | 0.1M |
No sell-side coverage available for MNPR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-5.23M | $-16.70M | $-10.55M | $-6.46M |
Net Income | $-3.89M | $-13.72M | $-8.52M | $-2.45M |
EPS (Diluted) | $-0.46 | $-1.85 | $-1.21 | $-0.73 |
Total Assets | $137.98M | $140.72M | $144.20M | $53.87M |
Total Liabilities | $2.59M | $2.89M | $2.64M | $1.66M |
Cash & Equivalents | $52.54M | $61.83M | $127.68M | $39.50M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 6.70M | 6.69M | 6.66M | 6.13M |
MNPR is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.